Why the study?
Does long-term therapeutic enoxaparin cause abnormal drug accumulation and clinical bleeding in patients with mild renal insufficiency?
Does long-term therapeutic enoxaparin cause abnormal drug accumulation and clinical bleeding in patients with mild renal insufficiency?
Patients receiving therapeutic enoxaparin for over 4 weeks with mild renal insufficiency may require laboratory monitoring to prevent drug accumulation and bleeding.
Answers are grounded in this paper and cite their sources.
Potential bleeding risk with long-term enoxaparin in mild renal impairment despite normal creatinine; case reports leave open need for anti-Xa monitoring.
Low-molecular-weight heparins, such as enoxaparin, are increasingly being used for treatment of venous thromboembolism. We describe two patients who received therapeutic enoxaparin for several months. Although their serum creatinine values were normal, both had mild renal insufficiency (creatinine clearance 60-70 ml/min), and both accumulated the drug abnormally and experienced clinical bleeding. These results suggest that patients receiving enoxaparin (or other low-molecular-weight heparins) in therapeutic doses for periods of more than 4 weeks should be considered for laboratory monitoring to avoid bleeding.
No takes yet. Share an insight, caveat, or question.
Busby et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: